Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals

Patsouris D., Li PP., Thapar D., Chapman J., Olefsky JM., Neels JG.

Animal Study on Type 2 Diabetes, published in Cell Metab (2008) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cell Metab (2008)
Reported sample size
—
Source database
Europe PMC
PMID
18840360
PMCID
PMC2630775
DOI
10.1016/j.cmet.2008.08.015
Citations
669

Abstract (original English)

Obese adipose tissue is characterized by infiltration of macrophages. We and others recently showed that a specific subset of macrophages is recruited to obese adipose and muscle tissue. This subset expresses CD11c and produces high levels of proinflammatory cytokines that are linked to the development of obesity-associated insulin resistance. Here, we used a conditional cell ablation system, based on transgenic expression of the diphtheria toxin receptor under the control of the CD11c promoter, to study the effects of depletion of CD11c+ cells in obese mouse models. Our results show that CD11c+ cell depletion results in rapid normalization of insulin sensitivity. Furthermore, CD11c+ cell ablation leads to a marked decrease in inflammatory markers, both locally and systemically, as reflected by gene expression and protein levels. Together, these results indicate that these CD11c+ cells are a potential therapeutic target for treatment of obesity-related insulin resistance and type II diabetes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
LiverAdipose TissueMacrophagesAnimalsMice, Inbred C57BLMice, TransgenicHumansMiceInsulin ResistanceObesity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research